Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

GLP-1 drugs linked to lower kidney failure risk in bipolar disorder (opens in a new tab)

medicalxpress.com · 2026-10-19

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 5 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All five claims match what the study reports.

  • 5 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5SupportedMayo Clinic researchers found that GLP-1 receptor agonists were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that, in adults with bipolar disorder and CKD stage ≤3, GLP-1 receptor agonist initiation was associated with lower risk of kidney replacement therapy versus DPP-4 inhibitors in the primary comparison and versus RAAS inhibitors in the secondary comparison. The story frames the finding associationally, which matches the observational evidence.

1

Study evidence

In propensity-score–matched cohorts (n=3,908 per group), initiating GLP-1 RA versus DPP-4 inhibitors was associated with lower adjusted hazard of kidney replacement therapy (KRT).aHR 0.56, 95% CI 0.50–0.64

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

After propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher among GLP-1 RA users versus RAAS inhibitor users (94.68% vs 89.77%; P<.001).KRT aHR 0.66 (reported in abstract)

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users.”
Claim 2 of 5SupportedThe study, published in the Journal of Clinical Psychiatry, suggests that a popular class of medications may offer an added benefit by helping protect kidney health in a high-risk group.View evidenceHide evidence

Why this verdict

The scientific framing is broadly supported: the profile reports lower observed KRT risk with GLP-1 RA use and describes the findings as exploratory and warranting prospective study, so a hedged statement that the drugs may offer an added kidney-health benefit is within the abstract evidence. The supplied paper profile does not independently verify the journal venue or the characterization of the drugs as 'popular,' but those details do not materially change the paper-evidence claim.

1

Study evidence

In propensity-score–matched cohorts (n=3,908 per group), initiating GLP-1 RA versus DPP-4 inhibitors was associated with lower adjusted hazard of kidney replacement therapy (KRT).aHR 0.56, 95% CI 0.50–0.64

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

After propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher among GLP-1 RA users versus RAAS inhibitor users (94.68% vs 89.77%; P<.001).KRT aHR 0.66 (reported in abstract)

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users.”
Claim 3 of 5SupportedResearchers analyzed de-identified electronic health record data from TriNetX and compared adults with bipolar disorder and mild-to-moderate chronic kidney disease who had newly started a GLP-1 medication with patients taking DPP-4 inhibitors or RAAS inhibitors, using statistical matching and up to five years of follow-up.View evidenceHide evidence

As statedup to five years

Why this verdict

The profile supports the described design: TriNetX real-world/EHR-derived data, adults with bipolar disorder and CKD stage ≤3, new-user active-comparator cohorts comparing GLP-1 RA initiators with DPP-4 inhibitor initiators primarily and RAAS inhibitor users secondarily, propensity score matching, Cox time-to-event analysis, and follow-up up to 5 years. The abstract profile supports the EHR/TriNetX source but does not itself emphasize 'de-identified' data.

1

Study evidence

In propensity-score–matched cohorts (n=3,908 per group), initiating GLP-1 RA versus DPP-4 inhibitors was associated with lower adjusted hazard of kidney replacement therapy (KRT).aHR 0.56, 95% CI 0.50–0.64

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

After propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher among GLP-1 RA users versus RAAS inhibitor users (94.68% vs 89.77%; P<.001).KRT aHR 0.66 (reported in abstract)

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users.”
Claim 4 of 5SupportedAcross both comparisons, GLP-1 use was associated with a lower risk of dialysis or kidney transplantation, and the pattern was generally consistent across sex, race, obesity status and use of psychiatric medications including lithium.View evidenceHide evidence

Why this verdict

The profile reports lower KRT risk in both the primary DPP-4 comparator cohort and the secondary RAAS comparator cohort. It also reports that benefits were consistent across sex, race, obesity status, and psychotropic medication subgroups including lithium. The story's 'generally consistent' wording appropriately avoids overstating the subgroup evidence, which at abstract depth lacks subgroup-specific estimates or interaction statistics.

1

Study evidence

In propensity-score–matched cohorts (n=3,908 per group), initiating GLP-1 RA versus DPP-4 inhibitors was associated with lower adjusted hazard of kidney replacement therapy (KRT).aHR 0.56, 95% CI 0.50–0.64

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

After propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher among GLP-1 RA users versus RAAS inhibitor users (94.68% vs 89.77%; P<.001).KRT aHR 0.66 (reported in abstract)

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users.”
Claim 5 of 5SupportedBecause the study was observational, it cannot establish that GLP-1 medications caused the lower risk, and the researchers said prospective studies are needed to determine whether GLP-1 medications directly slow kidney disease progression.View evidenceHide evidence

Why this verdict

The profile identifies the study as observational and states that the authors characterize the findings as exploratory and call for prospective studies to evaluate causality. This supports the story's caveat that the study cannot establish causation and that prospective studies are needed before concluding GLP-1 medications directly slow kidney disease progression. The exact quoted wording is not independently verifiable from the abstract-level profile, but the substance is supported.

1

Study evidence

In propensity-score–matched cohorts (n=3,908 per group), initiating GLP-1 RA versus DPP-4 inhibitors was associated with lower adjusted hazard of kidney replacement therapy (KRT).aHR 0.56, 95% CI 0.50–0.64

“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
2

Study evidence

After propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher among GLP-1 RA users versus RAAS inhibitor users (94.68% vs 89.77%; P<.001).KRT aHR 0.66 (reported in abstract)

“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Health care utilization was also a studied outcome, with reported lower adjusted hazards but nonsignificant post-matching HCU-free survival comparisons in the profile.

    The story focuses on dialysis/transplantation and does not mention the HCU outcome. This omission matters because HCU was part of the paper's stated outcomes and its survival-comparison results were less straightforward than the KRT findings.

    From new-user active-comparator cohort study; Secondary new-user active-comparator cohort (GLP-1 RA vs RAAS inhibitors)

  • Subgroup evidence is limited at abstract depth because subgroup-specific effect estimates, confidence intervals, interaction tests, and multiplicity handling are not provided.

    The story says the pattern was generally consistent but does not note that the abstract provides no subgroup-specific estimates or formal interaction statistics. This is a limitation on the strength of subgroup interpretation.

    From Prespecified subgroup/effect-modification analyses within propensity-score–matched observational cohorts

5 things the story did carry across
  • Primary comparison: GLP-1 RA initiation versus DPP-4 inhibitor initiation in adults with bipolar disorder and CKD stage ≤3, using TriNetX real-world data, propensity score matching, and Cox models over up to 5 years.
  • Secondary comparison: GLP-1 RA initiation versus RAAS inhibitor initiation, analyzed as a secondary active-comparator cohort.
  • Kidney replacement therapy outcome: GLP-1 RA use was associated with lower KRT risk in the primary and secondary comparisons.
  • Subgroup/effect-modification analyses assessed consistency across sex, race, ethnicity, obesity, and psychotropic medication use including lithium.
  • Causal limitation: findings are observational/exploratory and prospective studies are needed to assess whether associations reflect causal effects.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataAssess whether initiating GLP-1 receptor agonists (GLP-1 RA) is associated with reduced risk of kidney replacement therapy (KRT) and health care utilization (HCU) versus an active comparator (DPP-4 inhibitors) in adults with bipolar disorder and stage ≤3 chronic kidney disease using real-world data.new-user active-comparator cohort studyExpand

In plain English

Real-world new-user active-comparator cohort study using TriNetX data to compare initiation of GLP-1 receptor agonists (GLP-1 RA) versus DPP-4 inhibitors (primary comparator) in adults with bipolar disorder and stage ≤3 chronic kidney disease, assessing 5-year risk of kidney replacement therapy (KRT) and health care utilization (HCU). Propensity score matching and Cox proportional hazards models were used; primary matched cohorts included 3,908 participants per group. GLP-1 RA use was associated with lower adjusted hazards of KRT (aHR 0.56, 95% CI 0.50–0.64) and HCU (aHR 0.74, 95% CI 0.71–0.78) versus DPP-4 inhibitors; 5-year KRT-free survival after matching was 87.93% vs 84.63% (P < .001) and HCU-free survival did not differ significantly (P = .89). Secondary comparisons versus RAAS inhibitor users (matched n=2,539 per group) showed similar associations for KRT (aHR 0.66) and HCU (aHR 0.62), with higher matched 5-year KRT-free survival (94.68% vs 89.77%; P < .001) and no significant difference in HCU-free survival (P = .15). Benefits were reported as consistent across sex, race, obesity status, and psychotropic subgroups including lithium. The authors describe these as exploratory findings that warrant prospective study to assess causality.

Key findings

  • In propensity-score–matched cohorts (n=3,908 per group), initiating GLP-1 RA versus DPP-4 inhibitors was associated with lower adjusted hazard of kidney replacement therapy (KRT).aHR 0.56, 95% CI 0.50–0.64
  • In the same matched comparison, GLP-1 RA initiation was associated with lower adjusted hazard of health care utilization (HCU).aHR 0.74, 95% CI 0.71–0.78
“Using TriNetX, we conducted a real-world, new-user active-comparator cohort study among adults with BD+CKD initiating GLP-1 RA or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy (primary comparator)”
What this piece can’t prove
  • Authors describe findings as exploratory and state prospective studies are needed to evaluate whether the observed associations reflect causal effects.
2secondary dataCorroborate the GLP-1 RA association with KRT and HCU using a secondary active comparator cohort (RAAS inhibitor initiators).Secondary new-user active-comparator cohort (GLP-1 RA vs RAAS inhibitors)Expand

In plain English

Secondary analysis in TriNetX comparing new users of GLP-1 receptor agonists versus RAAS inhibitor initiators among adults with bipolar disorder and CKD (stage ≤3). Using propensity score matching (n=2,539 per group) and Cox regression over up to 5 years, GLP-1 RA use was associated with lower observed risk of kidney replacement therapy (KRT) and lower observed risk of health care utilization (HCU) in unadjusted/adjusted analyses; after matching, KRT-free survival was higher for GLP-1 RA users while HCU-free survival did not differ significantly.

Key findings

  • After propensity score matching (n=2,539 per group), 5-year KRT-free survival was higher among GLP-1 RA users versus RAAS inhibitor users (94.68% vs 89.77%; P<.001).KRT aHR 0.66 (reported in abstract)
  • Versus RAAS inhibitor initiators, GLP-1 RA use was reported with an adjusted hazard ratio for HCU of 0.62, but after propensity score matching HCU-free survival did not differ significantly between groups (P=.15).HCU aHR 0.62 (reported in abstract); post-PSM survival comparison P = .15 (no significant difference)
“with a secondary analysis versus renin-angiotensin-aldosterone system (RAAS) inhibitor users.”
What this piece can’t prove
  • Secondary observational analysis of electronic health record data; susceptible to residual confounding and indication bias despite propensity score matching.
  • Reported as exploratory; authors state prospective studies are needed to evaluate causality.

1 further detail could not be confirmed from the summary.

3secondary dataEvaluate effect modification/consistency of the GLP-1 RA associations across prespecified subgroups (sex, race, ethnicity, obesity, and psychotropic medication use, including lithium).Prespecified subgroup/effect-modification analyses within propensity-score–matched observational cohortsExpand

In plain English

The study prespecified subgroup/effect-modification analyses within propensity-score–matched TriNetX cohorts of adults with bipolar disorder and chronic kidney disease to assess whether associations of GLP-1 receptor agonist (GLP-1 RA) use with risk of kidney replacement therapy (KRT) and health-care utilization (HCU) varied by sex, race, ethnicity, obesity status, and psychotropic medication use (including lithium). The abstract reports that the observed benefits of GLP-1 RA use were consistent across these prespecified subgroups, but it does not present subgroup-specific effect estimates or formal interaction statistics.

Key findings

  • Prespecified subgroup analyses (sex, race, ethnicity, obesity, psychotropic medication use including lithium) were conducted within the matched/adjusted cohorts and the abstract reports that the observed benefits of GLP-1 RA use were consistent across these subgroups.
“Subgroup analyses examined effect modification by sex, race, ethnicity, obesity, and psychotropic medication use.”
What this piece can’t prove
  • The abstract does not describe multiplicity adjustment for multiple subgroup assessments.
  • Subgroup findings derive from observational, matched cohorts and are subject to residual confounding and potential limited power in strata.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 11 candidate papers

Candidate

SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.

Journal of Affective Disorders · 2026 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)

And 5 more candidates considered.